Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No clinical trials have been registered for familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome.
7 publications have been identified in PubMed for familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome. Research spans Case Report / Case Series (71%) and Review / Meta-Analysis (29%).
Tiwari V (2026). [PMID: 34283518](https://pubmed.ncbi.nlm.nih.gov/34283518/). *Unknown Journal*. [Review / Meta-Analysis]
Apele H (2025). [PMID: 41368866](https://pubmed.ncbi.nlm.nih.gov/41368866/). *Endocrinol Diabetes Metab Case Rep*. [Case Report / Case Series]
Ali I (2025). [PMID: 40330379](https://pubmed.ncbi.nlm.nih.gov/40330379/). *Cureus*. [Case Report / Case Series]
Ivanova NG (2024). [PMID: 38792634](https://pubmed.ncbi.nlm.nih.gov/38792634/). *Life (Basel)*. [Case Report / Case Series]
Fabbriciani G (2024). [PMID: 38916164](https://pubmed.ncbi.nlm.nih.gov/38916164/). *Reumatismo*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:37 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Jones G (2024). [PMID: 38780860](https://pubmed.ncbi.nlm.nih.gov/38780860/). *J Endocrinol Invest*. [Review / Meta-Analysis]
Alghubishi SA (2024). [PMID: 39539886](https://pubmed.ncbi.nlm.nih.gov/39539886/). *Cureus*. [Case Report / Case Series]
AI-curated news mentioning familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome
Updated Feb 19, 2026
A recent study demonstrates marked regression of calcinosis in patients with hyperphosphatemic familial tumoral calcinosis following treatment with canakinumab. This finding highlights the potential of canakinumab as a therapeutic option for this rare condition.